Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2014

Walls Marlena, Baxi Sangita M, Mehta Pramod P, Liu Kevin K-C, Zhu Jinjiang, Estrella Heather, Li Chunze, Zientek Michael, Zong Qing, Smeal Tod, Yin Min-Jean

Abstract excerpt

PURPOSE: Constitutive activation of phosphoinositide 3-kinase (PI3K) occurs frequently in many human tumors via either gene mutation in the p110α catalytic subunit of PI3K or functional loss of tumor suppressor PTEN. Patients with small-cell lung cancer (SCLC) have very poor prognosis and survival rates such that an effective targeted therapy is in strong demand for these patients. In this study, we characterized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Mice, SCID

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Small Cell Lung Carcinoma

Share to Thiophenes

Share to Triazoles

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 24240111
DOI: 10.1158/1078-0432.CCR-13-1663

Genes

PTEN
BCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.PMID 24240111Read ↗

Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.Semantic proximity Read ↗

Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directionsSemantic proximity Read ↗

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.Semantic proximity Read ↗

Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.Semantic proximity Read ↗

The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.Semantic proximity Read ↗

BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancerSemantic proximity Read ↗

PTEN Is a Potent Suppressor of Small Cell Lung CancerSemantic proximity Read ↗

The PI3k inhibitors: new hopes in the battle against advanced NSCLC.Semantic proximity Read ↗

A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.Semantic proximity Read ↗

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft ModelsSemantic proximity Read ↗

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.Semantic proximity Read ↗

Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.